GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Cyclically Adjusted Revenue per Share

Nuo Therapeutics (Nuo Therapeutics) Cyclically Adjusted Revenue per Share : $0.07 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nuo Therapeutics's adjusted revenue per share for the three months ended in Dec. 2023 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.07 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Nuo Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nuo Therapeutics was 14.50% per year. The lowest was 3.60% per year. And the median was 4.00% per year.

As of today (2024-05-14), Nuo Therapeutics's current stock price is $0.75. Nuo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.07. Nuo Therapeutics's Cyclically Adjusted PS Ratio of today is 10.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nuo Therapeutics was 46.75. The lowest was 0.40. And the median was 2.30.


Nuo Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Nuo Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Cyclically Adjusted Revenue per Share Chart

Nuo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.08 0.07

Nuo Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.07 0.07 0.07

Competitive Comparison of Nuo Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Nuo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Cyclically Adjusted PS Ratio falls into.



Nuo Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nuo Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.005/129.4194*129.4194
=0.005

Current CPI (Dec. 2023) = 129.4194.

Nuo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.032 98.790 0.042
201312 0.033 98.326 0.043
201403 0.017 99.695 0.022
201406 0.019 100.560 0.024
201409 0.014 100.428 0.018
201412 0.015 99.070 0.020
201503 0.038 99.621 0.049
201506 0.023 100.684 0.030
201509 0.017 100.392 0.022
201512 0.013 99.792 0.017
201603 0.011 100.470 0.014
201606 0.000 101.688 0.000
201609 0.018 101.861 0.023
201612 0.000 101.863 0.000
201703 0.017 102.862 0.021
201706 0.019 103.349 0.024
201709 0.010 104.136 0.012
201712 0.009 104.011 0.011
201803 0.007 105.290 0.009
201806 0.006 106.317 0.007
201809 0.011 106.507 0.013
201812 0.034 105.998 0.042
201903 0.002 107.251 0.002
201906 0.002 108.070 0.002
201909 0.002 108.329 0.002
201912 0.000 108.420 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.001 125.227 0.001
202212 0.002 125.222 0.002
202303 0.001 127.348 0.001
202306 0.003 128.729 0.003
202309 0.006 129.860 0.006
202312 0.005 129.419 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Nuo Therapeutics  (OTCPK:AURX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Nuo Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.75/0.07
=10.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nuo Therapeutics was 46.75. The lowest was 0.40. And the median was 2.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nuo Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713